Long-term outcomes in half-dose verteporfin photodynamic therapy for chronic central serous retinopathy
Open Access
- 1 December 2017
- journal article
- research article
- Published by Taylor & Francis in Clinical Ophthalmology
- Vol. ume 11, 2145-2149
Abstract
Objective: To evaluate the short- and long-term outcomes of half-dose verteporfin with photodynamic therapy (PDT) in the treatment of chronic central serous retinopathy (CSR). Design: Retrospective case series. Participants: 45 eyes in 39 patients with chronic CSR were included. Diagnosis of chronic CSR was confirmed by fluorescein angiography and persistence of subretinal fluid by optical coherence tomography for a minimum of 3 months duration. Methods: Each patient underwent treatment with half-dose verteporfin with full-fluence PDT; initial follow-up was defined as a 6–8 week visit following the treatment, and final follow-up ranged from 5 to 70 months. Results: The average follow-up period for treatment was 19.3 months. Best-corrected visual acuity increased from logMAR means of 0.52 to 0.42 (ppConclusion: Half-dose PDT is an effective treatment option for chronic CSR in a Canadian population, and it is both safe and durable. The positive treatment effect is realized rapidly, with the initial 6-week result highly correlated with the final follow-up result.Keywords
This publication has 20 references indexed in Scilit:
- Half-Fluence Versus Half-Dose Photodynamic Therapy in Chronic Central Serous ChorioretinopathyAmerican Journal of Ophthalmology, 2014
- Central Serous Chorioretinopathy: Update on Pathophysiology and TreatmentSurvey of Ophthalmology, 2013
- Central serous chorioretinopathy: a review of epidemiology and pathophysiologyClinical & Experimental Ophthalmology, 2012
- Standard-Fluence versus Low-Fluence Photodynamic Therapy in Chronic Central Serous Chorioretinopathy: A Nonrandomized Clinical TrialAmerican Journal of Ophthalmology, 2010
- Half-Dose Verteporfin Photodynamic Therapy for Acute Central Serous ChorioretinopathyOphthalmology, 2008
- Central serous chorioretinopathyActa Ophthalmologica, 2008
- Photodynamic Therapy for Chronic Central Serous ChorioretinopathyRetina, 2003
- Choroidal vascular remodelling in central serous chorioretinopathy after indocyanine green guided photodynamic therapy with verteporfin: a novel treatment at the primary disease levelBritish Journal of Ophthalmology, 2003
- Photodynamic therapy of subfoveal choroidal neovascularization in age-related macular degeneration with verteporfin: one-year results of 2 randomized clinical trials--TAP report. Treatment of age-related macular degeneration with photodynamic therapy (TAP) Study Group.1999
- Indocyanine green angiographic findings in central serous chorioretinopathyEye, 1995